INDICATIONS

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events... READ MORE

For US healthcare professionals

Heart-img

AS OF AUGUST 2025: Indicated for adults at increased risk for major adverse CV events1,2

Patients IconPatients Icon

IDENTIFY
Patients at Very High Risk

~50% of ASCVD patients are at very high risk for another CV event3,4,*
United States IconUnited States Icon

EXPLORE Broad Coverage and Affordability

Repatha® is covered for 96% of insured patients with established CVD and hypercholesterolemia5,†
Co-Pay Card IconCo-Pay Card Icon

ACCESS Amgen® SupportPlus

With the Repatha® Co-Pay Card, eligible commercial patients may pay as little as $15 per month‡

>5

million patients

have received Repatha® worldwide5,§

REVIEW SAFETY DATA
Have you seen
Amgen’s campaign?
Watch the commercial to learn what Repatha® can do for your patients

*Based on the proportion of patients with ASCVD at very high risk for a cardiovascular event using IQVIA LAAD claims data and patient data linked between Quest Diagnostics and IQVIA from January 2018 to December 2022 in the United States.2

†Includes commercial, health exchange, Medicaid, and Medicare lives, as of 01/20/25, based on MMIT data. Inclusion on formulary does not imply superior clinical efficacy or safety. This information is subject to change without notice. For the most up-to-date and complete information regarding coverage of Repatha®, please contact the relevant payer directly.

‡Eligibility criteria and program maximums apply. Please see full Terms and Conditions at Repatha.com/copaytcs.

§Cumulative post-market exposure estimates from July 2015 through July 2025, on patients that have received at least 1 dose (estimates assume administration) of the product, which was estimated using prescription claims data (IQVIA) for the U.S and units distributed (Amgen Finance Electronic Data Warehouse) with average drug utilization patterns (MarketScan claims data) for all other regions. Utilization assumptions were applied to calculate the unique number of patients.5

ASCVD = atherosclerotic cardiovascular disease; CV = cardiovascular; IMS Quintiles Virtual Information Access; LAAD, longitudinal access and adjudication data; MI, myocardial infarction.

References: 1. Repatha® (evolocumab) Prescribing Information, Amgen. 2. Amgen. Repatha® now indicated for adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL-C. News release; August 25, 2025. 3. Data on file, Amgen; 2023. 4. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80:1366-1418. 5. Data on file, Amgen; 2025.

Important Safety Information

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hypercholesterolemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Indications

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events.
  • As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia and in adults with heterozygous familial hypercholesterolemia (HeFH)

Please see full Prescribing Information.

Important Safety Information

Back To Top